Premium
Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy
Author(s) -
MORTON N.S.,
CAMU F.,
DORMAN T.,
KNUDSEN K.E.,
KVALSVIK O.,
NELLGARD P.,
SAINTMAURICE C.P.,
WILHELM W.,
COHEN L.A.
Publication year - 1997
Publication title -
pediatric anesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.704
H-Index - 82
eISSN - 1460-9592
pISSN - 1155-5645
DOI - 10.1046/j.1460-9592.1997.d01-39.x
Subject(s) - ondansetron , retching , medicine , nausea , anesthesia , vomiting , postoperative nausea and vomiting , tonsillectomy , antiemetic , adenoidectomy , placebo , alternative medicine , pathology
The efficacy, safety and resource implications of a single intravenous dose of ondansetron (0.1 mg·kg −1 , maximum 4 mg) were assessed in a multinational, multicentre, randomized, double‐blind, placebo‐controlled trial of 427 children aged 1–12 years, undergoing tonsillectomy with/without adenoidectomy. Emesis (retching and/or vomiting) and nausea were analysed separately. Significantly more ondansetron‐treated children had no episodes of emesis (127/212 (60%) vs 100/215 (47%); P =0.004) and experienced no postoperative nausea (135/211 (64%) vs 108/213 (51%); P =0.004) in the first 24 h. Ondansetron also reduced the number of emetic episodes ( P <0.001), the time to the first emetic episode ( P <0.001) and overall nausea severity ( P =0.003). Significantly fewer ondansetron‐treated children were rescued or withdrawn from the study (5% vs 10%; P =0.042). Fewer ondansetron‐treated patients required nursing intervention (34% vs 45%; P =0.007) and the average intervention time was significantly shorter (4.6 vs 8.1 minutes; P =0.001). Resources used to manage PONV were significantly reduced by ondansetron (43% vs 57%; P =0.014).